Compass Pathways partners Osmind on psychedelic therapy

Compass Pathways (CMPS) rose premarket after partnering with Osmind to educate over 1,000 US clinics on its COMP360 therapy. The collaboration prepares providers for potential FDA approval. This follows a 42% rally on Monday and Trump's executive order to fast-track psychedelic drug reviews.